Supplementary Figure S6 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma

Jean‐Baptiste Assié; Clément Meiller; Esther Stern; Julie Lasvergnas; Maya Arnould; Long Pan; François Montagne; Ruth Sequeiros; Charles Al Zreibi; Elaine Del Nery; Auguste Genovesio; Sylvie Lantuéjoul; Françoise Le Pimpec‐Barthes; Jessica Zucman-Rossi; Marie-Claude Jaurand; Christophe Blanquart; Ori Wald; Didier Jean

doi:10.1158/0008-5472.30986274

Supplementary Figure S6 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma

2026 Open access

Read full text

Authors: Jean‐Baptiste Assié, Clément Meiller, Esther Stern, Julie Lasvergnas, Maya Arnould, Long Pan, François Montagne, Ruth Sequeiros, Charles Al Zreibi, Elaine Del Nery, Auguste Genovesio, Sylvie Lantuéjoul

+6 more

Françoise Le Pimpec‐Barthes, Jessica Zucman-Rossi, Marie-Claude Jaurand, Christophe Blanquart, Ori Wald, Didier Jean

DOI: 10.1158/0008-5472.30986274

Cited by: 0

Abstract

Exclusivity between mutations in the TP53 gene and heterozygous deletions in the RPL5 and RPL22 genes.

Fields of Study & Subjects

Occupational and environmental lung diseases Pleural and Pulmonary Diseases Myasthenia Gravis and Thymoma

Publication details

Publication date: 2 January 2026